Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764

Reovirus Therapy of Tumors with Activated Ras Pathway

Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

Rampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552

Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins

Wickham, T. J., Tzeng, E., Shears, L. L., Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A., & Kovesdi, I. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8221-8229.1997 · Cited by 488

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432

Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenoviridae

Roelvink, P. W., Lee, G. M., Einfeld, D. A., Kovesdi, I., & Wickham, T. J. (1999) · Science · doi:10.1126/science.286.5444.1568 · Cited by 406

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Nemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 404

Intergeneric poliovirus recombinants for the treatment of malignant glioma

Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., & Wimmer, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6803 · Cited by 363

Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells

Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339

A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy

Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., & Kim, J. H. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.9-1323 · Cited by 337

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294

A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma

Hallenbeck, P. L., Chang, Y.-N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., & Chiang, Y. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950017725 · Cited by 283

p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication

Harada, J. N., & Berk, A. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5333-5344.1999 · Cited by 259

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer

Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.

Mineta, T., Rabkin, S. D., & Martuza, R. L. (1994) · PubMed · Cited by 240

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen

Kurihara, T., Brough, D. E., Kovesdi, I., & Kufe, D. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9180 · Cited by 238

Two regions of the adenovirus early region 1A proteins are required for transformation

Whyte, P., Ruley, H. E., & Harlow, E. (1988) · Journal of Virology · doi:10.1128/jvi.62.1.257-265.1988 · Cited by 226

Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein

Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)

Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., & Michael Korn, W. (2000) · Nature Medicine · doi:10.1038/80466 · Cited by 189

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.

Whitley, R. J., Kern, E. R., Chatterjee, S., Chou, J., & Roizman, B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116527 · Cited by 188

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., & Kirn, D. H. (2000) · PubMed · Cited by 178

Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.

Wildner, O., Blaese, R. M., & Morris, J. C. (1999) · PubMed · Cited by 177

Antineoplasic activity of parvoviruses

Rommelaere, J., & Cornelis, J. J. (1991) · Journal of Virological Methods · doi:10.1016/0166-0934(91)90024-t · Cited by 176

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

Yu, D., Chen, Y., Dilley, J., Li, Y., Embry, M. G., Zhang, H., Nguyen, N. N. M., Amin, P., Oh, J., & Henderson, D. (2001) · PubMed · Cited by 173

Use of preferentially replicating bacteria for the treatment of cancer

Sznol, M., Lin, S. L., Bermudes, D., Zheng, L.-M., & King, I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9818 · Cited by 170

In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity

Toda, M., Martuza, R. L., Kojima, H., & Rabkin, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4457 · Cited by 161

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

Kirn, D. H. (2000) · Oncogene · doi:10.1038/sj.onc.1204094 · Cited by 148

Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- and Augmentation of Its Cytotoxicity2

Lorence, R. M., Rood, P. A., & Kelley, K. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1305 · Cited by 145

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

Hermiston, T. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9973 · Cited by 134

The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle

Goodrum, F. D., & Ornelles, D. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.1.548-561.1997 · Cited by 126

Reovirus as a novel oncolytic agent

Norman, K. L., & Lee, P. W. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9871 · Cited by 124

DIVISION OF MICROBIOLOGY: PRESENT STATUS OF ONCOLYTIC VIRUS STUDIES*

Southam, C. M. (1960) · Transactions of the New York Academy of Sciences · doi:10.1111/j.2164-0947.1960.tb00739.x · Cited by 115

A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alterations in the CD8 T Cell Repertoire

Batliwalla, F., Bateman, B. A., Serrano, D., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401771 · Cited by 114

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation

Mukherjee, S., Haenel, T., Himbeck, R. P., Scott, B., Ramshaw, I. A., Lake, R., Harnett, G. B., Phillips, P. A., Morey, S., Smith, D. W., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700133 · Cited by 111

Transcriptional targeting of herpes simplex virus for cell-specific replication

Miyatake, S., Iyer, A., Martuza, R. L., et al. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5124-5132.1997 · Cited by 108

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

Heise, C. C., Lemmon, M. J., & Kirn, D. H. (2000) · PubMed · Cited by 100

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

McCart, J., Puhlmann, M., Lee, J. K., Hu, Y., Libutti, S. K., Alexander, H., & BARTLETT, D. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301237 · Cited by 94

Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

Conry, R. M., Khazaeli, M. B., Saleh, M. N., Allen, K. O., Barlow, D. L., Moore, S. E., Craig, D., Arani, R. B., Schlom, J., & LoBuglio, A. F. (1999) · PubMed · Cited by 90

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

Herrlinger, U., Kramm, C. M., Aboody-Guterman, K. S., Silver, J., Ikeda, K., Johnston, K. J., Pechan, P., Barth, R., Finkelstein, D. M., Chiocca, E. A., et al. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300643 · Cited by 80

Adenovirus Type 5 Viral Particles Pseudotyped with Mutagenized Fiber Proteins Show Diminished Infectivity of Coxsackie B-Adenovirus Receptor-Bearing Cells

Jakubczak, J. L., Rollence, M. L., Stewart, D. A., Jafari, J. D., Seggern, D. J. V., Nemerow, G. R., Stevenson, S. C., & Hallenbeck, P. L. (2001) · Journal of Virology · doi:10.1128/jvi.75.6.2972-2981.2001 · Cited by 71

Highly Efficient Transduction and Expression of Cytokine Genes in Human Tumor Cells by Means of Autonomous Parvovirus Vectors; Generation of Antitumor Responses in Recipient Mice

Haag, A. F., Menten, P., Damme, J. V., et al. (2000) · Human Gene Therapy · doi:10.1089/10430340050015789 · Cited by 64

Progress and problems with the use of viral vectors for gene therapy

Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347

Telomerase-Specific Replication-Selective Virotherapy for Human Cancer

Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1075-3 · Cited by 262

Gene Therapy for Malignant Glioma: Current Clinical Status

Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161

Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’)

Taki, M., Kagawa, S., Nishizaki, M., Mizuguchi, H., Hayakawa, T., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., & Fujiwara, T. (2005) · Oncogene · doi:10.1038/sj.onc.1208460 · Cited by 86